Global Allogenic Stem Cell Therapy Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application

Report ID: ARS12445 | Category: Healthcare | Pages: 112 | Format: PDF | Published Date: December 18,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3350.00 Multi User-$5700.00

Report Description
View Table of Contents

Report Summary

This report aims to provide a comprehensive presentation of the global market for Allogenic Stem Cell Therapy, with and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Allogenic Stem Cell Therapy.

The Allogenic Stem Cell Therapy market size considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Allogenic Stem Cell Therapy market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Allogenic Stem Cell Therapy manufacturers, new entrants, and industry chain related companies in this market with information for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

The global Allogenic Stem Cell Therapy market size in 2022 is 994.9 million US dollars, and it is expected to be 1920.3 million US dollars by 2029, with a compound annual growth rate of 9.85% expected in 2023-2029.

MARKET COMPETITIVE LANDSCAPE:
The main players in the Allogenic Stem Cell Therapy market include Athersys Inc. (U.S.), Mesoblast Ltd (Australia), Biorestorative Therapies Inc. (U.S.), Pluristem Inc. (Israel), and Brainstorm Cell Limited. (U.S.). The share of the top 3 players in the Allogenic Stem Cell Therapy market is XX%.

REGION SHARE:
The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and North America accounted for XX%, Europe accounted for XX% of Allogenic Stem Cell Therapy market, and Asia Pacific accounted for XX%.

SEGMENT OVERVIEW:
The report segments the market by Type and Application. Adult Stem Cells accounted for XX% of Allogenic Stem Cell Therapy market in 2022. Human Embryonic Stem Cells share of XX%.
Therapeutic Companies accounted for XX% of the Allogenic Stem Cell Therapy market in 2022. Cell and Tissues Banks accounts for XX%.

Chapter Outline
Chapter 1: Introduces the product overview, and global Allogenic Stem Cell Therapy market status and forecast by region.
Chapters 2-3: Segmented the global Allogenic Stem Cell Therapy market by type, and application. Analyze the revenue of market segments from different perspectives.
Chapter 4: Analysis of the competitive environment of Allogenic Stem Cell Therapy market participants. This mainly includes the revenue and market share of the top players, along with the players' M&A and expansion in recent years.
Chapters 5-9: Provide North America, Europe, Asia-Pacific, Latin America and Middle East & Africa Allogenic Stem Cell Therapy market country segmentation data.
Chapter 10: Analyzes the main companies in the Allogenic Stem Cell Therapy industry, including their main businesses, products/services, revenue, gross margin, and the latest developments.
Chapter 11: Introduces the market dynamics, the trends factors and drivers factors of the market, and the challenges and restraints faced by manufacturers in the industry.
Chapter 12: The main points and conclusions of the report.
Chapter 13: Concludes with an explanation of the data sources and research methods.

Highlights-Regions

North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia Pacific
China
Japan
South Korea
India
Southeast Asia
South America
Brazil
Argentina
Colombia
MEA
Saudi Arabia
Egypt
Nigeria

Player list
Athersys Inc. (U.S.)
Mesoblast Ltd (Australia)
Biorestorative Therapies Inc. (U.S.)
Pluristem Inc. (Israel)
Brainstorm Cell Limited. (U.S.)
ViaCyte Inc. (U.S.)
Gamida Cell (U.S.)
HOPE BIOSCIENCES (U.S.)
Cellular Biomedicine Group (U.S.)
Smith+Nephew (U.K.)
MEDIPOST (South Korea)
ANTEROGEN.CO, LTD. (South Korea)
NuVasive Inc. (U.S.)
RTI Surgical (U.S.)
AlloSource (U.S.)
JCR Pharmaceuticals Co. Ltd. (Japan)
Takeda Pharmaceutical Company Limited (Japan)

Types list
Adult Stem Cells
Human Embryonic Stem Cells
Induced Pluripotent Stem Cells

Application list
Therapeutic Companies
Cell and Tissues Banks
Tools and Reagent Companies
Service Companies

Table of Content

1 Allogenic Stem Cell Therapy Market Overview
1.1 Allogenic Stem Cell Therapy Product Overview
1.1.1 Allogenic Stem Cell Therapy Product Scope
1.1.2 Allogenic Stem Cell Therapy Market Status and Outlook
1.2 Global Allogenic Stem Cell Therapy Market Size Overview by Region 2018 VS 2022VS 2029
1.3 Global Allogenic Stem Cell Therapy Market Size by Region (2018-2029)
1.4 Global Allogenic Stem Cell Therapy Historic Market Size by Region (2018-2023)
1.5 Global Allogenic Stem Cell Therapy Market Size Forecast by Region (2023-2029)
1.6 Key Regions, Allogenic Stem Cell Therapy Market Size (2018-2029)
1.6.1 North America Allogenic Stem Cell Therapy Market Size (2018-2029)
1.6.2 Europe Allogenic Stem Cell Therapy Market Size (2018-2029)
1.6.3 Asia-Pacific Allogenic Stem Cell Therapy Market Size (2018-2029)
1.6.4 Latin America Allogenic Stem Cell Therapy Market Size (2018-2029)
1.6.5 Middle East & Africa Allogenic Stem Cell Therapy Market Size (2018-2029)
2 Allogenic Stem Cell Therapy Market Overview by Type
2.3 Global Allogenic Stem Cell Therapy Market Size by Type: 2018 VS 2022 VS 2029
2.4 Global Allogenic Stem Cell Therapy Historic Market Size by Type (2018-2023)
2.5 Global Allogenic Stem Cell Therapy Forecasted Market Size by Type (2023-2029)
2.6 Key Regions Market Size Segment by Type (2018-2029)
2.6.1 North America Allogenic Stem Cell Therapy Market Size Breakdown by Type (2018-2029)
2.6.2 Europe Allogenic Stem Cell Therapy Market Size Breakdown by Type
2.6.3 Asia-Pacific Allogenic Stem Cell Therapy Market Size Breakdown by Type
2.6.4 Latin America Allogenic Stem Cell Therapy Market Size Breakdown by Type
2.6.5 Middle East and Africa Allogenic Stem Cell Therapy Market Size Breakdown by Type
3 Allogenic Stem Cell Therapy Market Overview by Application
3.3 Global Allogenic Stem Cell Therapy Market Size by Application: 2018 VS 2022 VS 2029
3.4 Global Allogenic Stem Cell Therapy Historic Market Size by Application (2018-2023)
3.5 Global Allogenic Stem Cell Therapy Forecasted Market Size by Application (2023-2029)
3.6 Key Regions Market Size Segment by Application (2018-2029)
3.6.1 North America Allogenic Stem Cell Therapy Market Size Breakdown by Application (2018-2029)
3.6.2 Europe Allogenic Stem Cell Therapy Market Size Breakdown by Application
3.6.3 Asia-Pacific Allogenic Stem Cell Therapy Market Size Breakdown by Application
3.6.4 Latin America Allogenic Stem Cell Therapy Market Size Breakdown by Application
3.6.5 Middle East and Africa Allogenic Stem Cell Therapy Market Size Breakdown by Application
4 Allogenic Stem Cell Therapy Competition Analysis by Players
4.1 Global Allogenic Stem Cell Therapy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Allogenic Stem Cell Therapy as of 2022)
4.3 Date of Key Players Enter into Allogenic Stem Cell Therapy Market
4.4 Global Top Players Allogenic Stem Cell Therapy Headquarters and Area Served
4.5 Key Players Allogenic Stem Cell Therapy Product Solution and Service
4.6 Competitive Status
4.6.1 Allogenic Stem Cell Therapy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 North America Allogenic Stem Cell Therapy Market Segment by Country
5.1 North America Allogenic Stem Cell Therapy Market Size by Country (2018-2029)
5.2 United States
5.3 Canada
6 Europe Allogenic Stem Cell Therapy Market Segment by Country
6.1 Europe Allogenic Stem Cell Therapy Market Size by Country (2018-2029)
6.2 Germany
6.3 France
6.4 U.K.
6.5 Italy
6.6 Russia
6.7 Nordic
6.8 Rest of Europe
7 Asia-Pacific Allogenic Stem Cell Therapy Market Segment by Country
7.1 Asia-Pacific Allogenic Stem Cell Therapy Market Size by Region (2018-2029)
7.2 China
7.3 Japan
7.4 South Korea
7.5 Southeast Asia
7.6 India
7.7 Australia
7.8 Rest of Asia-Pacific
8 Latin America Allogenic Stem Cell Therapy Market Segment by Country
8.1 Latin America Allogenic Stem Cell Therapy Market Size by Country (2018-2029)
8.2 Mexico
8.3 Brazil
8.4 Rest of Latin America
9 Middle East and Africa Allogenic Stem Cell Therapy Market Segment by Country
9.1 Middle East & Africa Allogenic Stem Cell Therapy Market Size by Country (2018-2029)
9.2 Turkey
9.3 Saudi Arabia
9.4 UAE
9.5 Rest of Middle East & Africa
10 Manufacturers Profiles
10.1  Athersys Inc. (U.S.)
10.1.1 Athersys Inc. (U.S.) Information
10.1.2 Business Overview
10.1.3 Athersys Inc. (U.S.) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.1.4 Allogenic Stem Cell Therapy Products Offered
10.1.5 Athersys Inc. (U.S.) Recent Development
10.2  Mesoblast Ltd (Australia)
10.2.1 Mesoblast Ltd (Australia) Information
10.2.2 Business Overview
10.2.3 Mesoblast Ltd (Australia) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.2.4 Allogenic Stem Cell Therapy Products Offered
10.2.5 Mesoblast Ltd (Australia) Recent Development
10.3  Biorestorative Therapies Inc. (U.S.)
10.3.1 Biorestorative Therapies Inc. (U.S.) Information
10.3.2 Business Overview
10.3.3 Biorestorative Therapies Inc. (U.S.) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.3.4 Allogenic Stem Cell Therapy Products Offered
10.3.5 Biorestorative Therapies Inc. (U.S.) Recent Development
10.4  Pluristem Inc. (Israel)
10.4.1 Pluristem Inc. (Israel) Information
10.4.2 Business Overview
10.4.3 Pluristem Inc. (Israel) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.4.4 Allogenic Stem Cell Therapy Products Offered
10.4.5 Pluristem Inc. (Israel) Recent Development
10.5  Brainstorm Cell Limited. (U.S.)
10.5.1 Brainstorm Cell Limited. (U.S.) Information
10.5.2 Business Overview
10.5.3 Brainstorm Cell Limited. (U.S.) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.5.4 Allogenic Stem Cell Therapy Products Offered
10.5.5 Brainstorm Cell Limited. (U.S.) Recent Development
10.6  ViaCyte Inc. (U.S.)
10.6.1 ViaCyte Inc. (U.S.) Information
10.6.2 Business Overview
10.6.3 ViaCyte Inc. (U.S.) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.6.4 Allogenic Stem Cell Therapy Products Offered
10.6.5 ViaCyte Inc. (U.S.) Recent Development
10.7  Gamida Cell (U.S.)
10.7.1 Gamida Cell (U.S.) Information
10.7.2 Business Overview
10.7.3 Gamida Cell (U.S.) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.7.4 Allogenic Stem Cell Therapy Products Offered
10.7.5 Gamida Cell (U.S.) Recent Development
10.8  HOPE BIOSCIENCES (U.S.)
10.8.1 HOPE BIOSCIENCES (U.S.) Information
10.8.2 Business Overview
10.8.3 HOPE BIOSCIENCES (U.S.) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.8.4 Allogenic Stem Cell Therapy Products Offered
10.8.5 HOPE BIOSCIENCES (U.S.) Recent Development
10.9  Cellular Biomedicine Group (U.S.)
10.9.1 Cellular Biomedicine Group (U.S.) Information
10.9.2 Business Overview
10.9.3 Cellular Biomedicine Group (U.S.) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.9.4 Allogenic Stem Cell Therapy Products Offered
10.9.5 Cellular Biomedicine Group (U.S.) Recent Development
10.10  Smith+Nephew (U.K.)
10.10.1 Smith+Nephew (U.K.) Information
10.10.2 Business Overview
10.10.3 Smith+Nephew (U.K.) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.10.4 Allogenic Stem Cell Therapy Products Offered
10.10.5 Smith+Nephew (U.K.) Recent Development
10.11  MEDIPOST (South Korea)
10.11.1 MEDIPOST (South Korea) Information
10.11.2 Business Overview
10.11.3 MEDIPOST (South Korea) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.11.4 Allogenic Stem Cell Therapy Products Offered
10.11.5 MEDIPOST (South Korea) Recent Development
10.12  ANTEROGEN.CO, LTD. (South Korea)
10.12.1 ANTEROGEN.CO, LTD. (South Korea) Information
10.12.2 Business Overview
10.12.3 ANTEROGEN.CO, LTD. (South Korea) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.12.4 Allogenic Stem Cell Therapy Products Offered
10.12.5 ANTEROGEN.CO, LTD. (South Korea) Recent Development
10.13  NuVasive Inc. (U.S.)
10.13.1 NuVasive Inc. (U.S.) Information
10.13.2 Business Overview
10.13.3 NuVasive Inc. (U.S.) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.13.4 Allogenic Stem Cell Therapy Products Offered
10.13.5 NuVasive Inc. (U.S.) Recent Development
10.14  RTI Surgical (U.S.)
10.14.1 RTI Surgical (U.S.) Information
10.14.2 Business Overview
10.14.3 RTI Surgical (U.S.) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.14.4 Allogenic Stem Cell Therapy Products Offered
10.14.5 RTI Surgical (U.S.) Recent Development
10.15  AlloSource (U.S.)
10.15.1 AlloSource (U.S.) Information
10.15.2 Business Overview
10.15.3 AlloSource (U.S.) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.15.4 Allogenic Stem Cell Therapy Products Offered
10.15.5 AlloSource (U.S.) Recent Development
10.16  JCR Pharmaceuticals Co. Ltd. (Japan)
10.16.1 JCR Pharmaceuticals Co. Ltd. (Japan) Information
10.16.2 Business Overview
10.16.3 JCR Pharmaceuticals Co. Ltd. (Japan) Allogenic Stem Cell Therapy Revenue, Gross Margin
10.16.4 Allogenic Stem Cell Therapy Products Offered
10.16.5 JCR Pharmaceuticals Co. Ltd. (Japan) Recent Development
10.17  Takeda Pharmaceutical Company Limited (Japan) 
10.17.1 Takeda Pharmaceutical Company Limited (Japan)  Information
10.17.2 Business Overview
10.17.3 Takeda Pharmaceutical Company Limited (Japan)  Allogenic Stem Cell Therapy Revenue, Gross Margin
10.17.4 Allogenic Stem Cell Therapy Products Offered
10.17.5 Takeda Pharmaceutical Company Limited (Japan)  Recent Development
11 Allogenic Stem Cell Therapy Market Dynamics
11.1 Allogenic Stem Cell Therapy Industry Trends
11.2 Allogenic Stem Cell Therapy Growth Drivers
11.3 Allogenic Stem Cell Therapy Market Challenges
11.4 Allogenic Stem Cell Therapy Market Restraints
12 Research Findings and Conclusion
13 Methodology and Data Source
13.1 A Methodology
13.1.1 Research Process
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 B Data Source
13.2.1 Legal Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Global Allogenic Stem Cell Therapy Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?